Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anserine is a **naturally occurring dipeptide** composed of beta-alanine and 3-methylhistidine. It is a methylated derivative of carnosine, primarily found in skeletal muscles and brains of birds, fish, and some mammals, as well as in human kidney tissue[1][3][4][5][6]. Anserine has several reported **biological properties**, including *antioxidant*, *pH buffering*, *metal ion chelation*, *anti-inflammatory*, and *anti-aggregation* effects[3][5][7]. A notable mechanism is its inhibition of the enzyme p300 histone acetyltransferase, which has been associated with anti-inflammatory and potential cardioprotective effects[5]. Some studies also report potential *anti-fatigue*, *anti-obesity*, and *cognitive-protective* actions, though anserine is not an FDA-approved pharmaceutical and is typically marketed as a dietary supplement or studied as a nutraceutical ingredient[1][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anserine.